Preclinical Mouse Models to Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo

Molecular Pharmaceutics

Volumn 12, Issue 12, 2015, Pages 4259-4269

  Durmus, Selvi ^a   Lozano Mena, Gloria ^a,b   Van Esch, Anita ^a   Wagenaar, Els ^a   Van Tellingen, Olaf ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

DDI; drug drug interactions; hepatic uptake; methotrexate; OATP1B1; OATP1B3; plasma disposition; rifampicin; telmisartan

Indexed keywords

METHOTREXATE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER POLYPEPTIDE 1A; ORGANIC ANION TRANSPORTER POLYPEPTIDE 1B; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TELMISARTAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CARRIER PROTEIN; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG POTENTIATION; DRUG PROTEIN BINDING; GENE OVEREXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER HOMOGENATE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; DRUG INTERACTION; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT;

EID: 84948989540     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00453     Document Type: Article

References (44)

1. Klaassen, C. D.; Aleksunes, L. M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation Pharmacol Rev. 2010, 62 (1) 1-96 10.1124/pr.109.002014
2. Shitara, Y.; Maeda, K.; Ikejiri, K.; Yoshida, K.; Horie, T.; Sugiyama, Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in the hepatic clearance and intestinal absorption Biopharm. Drug Dispos. 2013, 34 (1) 45-78 10.1002/bdd.1823
3. Hagenbuch, B.; Stieger, B. The SLCO (former SLC21) superfamily of transporters Mol. Aspects Med. 2013, 34 (2-3) 396-412 10.1016/j.mam.2012.10.009
4. van de Steeg, E.; van Esch, A.; Wagenaar, E.; Kenworthy, K. E.; Schinkel, A. H. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice Clin. Cancer Res. 2013, 19 (4) 821-832 10.1158/1078-0432.CCR-12-2080
5. van de Steeg, E.; Wagenaar, E.; van der Kruijssen, C. M.; Burggraaff, J. E.; de Waart, D. R.; Elferink, R. P.; Kenworthy, K. E.; Schinkel, A. H. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs J. Clin. Invest. 2010, 120 (8) 2942-2952 10.1172/JCI42168
6. Iusuf, D.; Hendrikx, J. J.; van Esch, A.; van de Steeg, E.; Wagenaar, E.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel Int. J. Cancer 2015, 136 (1) 225-233 10.1002/ijc.28970
7. Iusuf, D.; Sparidans, R. W.; van Esch, A.; Hobbs, M.; Kenworthy, K. E.; van de Steeg, E.; Wagenaar, E.; Beijnen, J. H.; Schinkel, A. H. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice Mol. Pharmaceutics 2012, 9 (9) 2497-2504 10.1021/mp300108c
8. Durmus, S.; Naik, J.; Buil, L.; Wagenaar, E.; van Tellingen, O.; Schinkel, A. H. In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters Int. J. Cancer 2014, 135 (7) 1700-1710 10.1002/ijc.28797
9. Ieiri, I.; Higuchi, S.; Sugiyama, Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs Expert Opin. Drug Metab. Toxicol. 2009, 5 (7) 703-729 10.1517/17425250902976854
10. Kalliokoski, A.; Niemi, M. Impact of OATP transporters on pharmacokinetics Br. J. Pharmacol. 2009, 158 (3) 693-705 10.1111/j.1476-5381.2009.00430.x
11. Yoshida, K.; Maeda, K.; Sugiyama, Y. Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies Clin. Pharmacol. Ther. 2012, 91 (6) 1053-1064 10.1038/clpt.2011.351
12. Takane, H.; Kawamoto, K.; Sasaki, T.; Moriki, K.; Moriki, K.; Kitano, H.; Higuchi, S.; Otsubo, K.; Ieiri, I. Life-threatening toxicities in a patient with UGT1A1∗6/∗28 and SLCO1B1∗15/∗15 genotypes after irinotecan-based chemotherapy Cancer Chemother. Pharmacol. 2009, 63 (6) 1165-1169 10.1007/s00280-008-0864-x
13. Trevino, L. R.; Shimasaki, N.; Yang, W.; Panetta, J. C.; Cheng, C.; Pei, D.; Chan, D.; Sparreboom, A.; Giacomini, K. M.; Pui, C. H.; Evans, W. E.; Relling, M. V. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects J. Clin. Oncol. 2009, 27 (35) 5972-5978 10.1200/JCO.2008.20.4156
14. van de Steeg, E.; Stranecky, V.; Hartmannova, H.; Noskova, L.; Hrebicek, M.; Wagenaar, E.; van Esch, A.; de Waart, D. R.; Oude Elferink, R. P.; Kenworthy, K. E.; Sticova, E.; al Edreesi, M.; Knisely, A. S.; Kmoch, S.; Jirsa, M.; Schinkel, A. H. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver J. Clin. Invest. 2012, 122 (2) 519-528 10.1172/JCI59526
15. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-236 10.1038/nrd3028
16. Prueksaritanont, T.; Chu, X.; Gibson, C.; Cui, D.; Yee, K. L.; Ballard, J.; Cabalu, T.; Hochman, J. Drug-drug interaction studies: regulatory guidance and an industry perspective AAPS J. 2013, 15 (3) 629-645 10.1208/s12248-013-9470-x
17. Hu, S.; Mathijssen, R. H.; de Bruijn, P.; Baker, S. D.; Sparreboom, A. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations Br. J. Cancer 2014, 110 (4) 894-898 10.1038/bjc.2013.811
18. Nieuweboer, A. J.; Hu, S.; Gui, C.; Hagenbuch, B.; Ghobadi Moghaddam-Helmantel, I. M.; Gibson, A. A.; de Bruijn, P.; Mathijssen, R. H.; Sparreboom, A. Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel Cancer Res. 2014, 74 (11) 3137-3145 10.1158/0008-5472.CAN-13-3634
19. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1 Drug Metab. Dispos. 2006, 34 (7) 1229-1236 10.1124/dmd.106.009290
20. Karlgren, M.; Ahlin, G.; Bergstrom, C. A.; Svensson, R.; Palm, J.; Artursson, P. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions Pharm. Res. 2012, 29 (2) 411-426 10.1007/s11095-011-0564-9
21. Kindla, J.; Muller, F.; Mieth, M.; Fromm, M. F.; Konig, J. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport Drug Metab. Dispos. 2011, 39 (6) 1047-1053 10.1124/dmd.110.037622
22. Noe, J.; Portmann, R.; Brun, M. E.; Funk, C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos. 2007, 35 (8) 1308-1314 10.1124/dmd.106.012930
23. Chang, J. H.; Ly, J.; Plise, E.; Zhang, X.; Messick, K.; Wright, M.; Cheong, J. Differential Effects of Rifampin and Ketoconazole on the Blood and Liver Concentration of Atorvastatin in Wild-Type and Cyp3a and Oatp1a/b Knockout Mice Drug Metab. Dispos. 2014, 42 (6) 1067-1073 10.1124/dmd.114.057968
24. Chu, X.; Bleasby, K.; Evers, R. Species differences in drug transporters and implications for translating preclinical findings to humans Expert Opin. Drug Metab. Toxicol. 2013, 9 (3) 237-252 10.1517/17425255.2013.741589
25. Grime, K.; Paine, S. W. Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement Drug Metab. Dispos. 2013, 41 (2) 372-378 10.1124/dmd.112.049312
26. Peters, J.; Eggers, K.; Oswald, S.; Block, W.; Lutjohann, D.; Lammer, M.; Venner, M.; Siegmund, W. Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals Drug Metab. Dispos. 2012, 40 (3) 522-528 10.1124/dmd.111.042267
27. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans J. Pharmacol. Exp. Ther. 2004, 311 (1) 139-146 10.1124/jpet.104.068056
28. van Tellingen, O.; van der Woude, H. R.; Beijnen, J. H.; van Beers, C. J.; Nooyen, W. J. Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids J. Chromatogr., Biomed. Appl. 1989, 488 (2) 379-388 10.1016/S0378-4347(00)82962-X
29. Tirona, R. G.; Leake, B. F.; Wolkoff, A. W.; Kim, R. B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation J. Pharmacol. Exp. Ther. 2003, 304 (1) 223-228 10.1124/jpet.102.043026
30. Vavricka, S. R.; Van Montfoort, J.; Ha, H. R.; Meier, P. J.; Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver Hepatology 2002, 36 (1) 164-172 10.1053/jhep.2002.34133
31. de Graan, A. J.; Lancaster, C. S.; Obaidat, A.; Hagenbuch, B.; Elens, L.; Friberg, L. E.; de Bruijn, P.; Hu, S.; Gibson, A. A.; Bruun, G. H.; Corydon, T. J.; Mikkelsen, T. S.; Walker, A. L.; Du, G.; Loos, W. J.; van Schaik, R. H.; Baker, S. D.; Mathijssen, R. H.; Sparreboom, A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel Clin. Cancer Res. 2012, 18 (16) 4433-40 10.1158/1078-0432.CCR-12-0761
32. Higgins, J. W.; Bao, J. Q.; Ke, A. B.; Manro, J. R.; Fallon, J. K.; Smith, P. C.; Zamek-Gliszczynski, M. J. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein Drug Metab. Dispos. 2014, 42 (1) 182-92 10.1124/dmd.113.054783
33. Salphati, L.; Chu, X.; Chen, L.; Prasad, B.; Dallas, S.; Evers, R.; Mamaril-Fishman, D.; Geier, E. G.; Kehler, J.; Kunta, J.; Mezler, M.; Laplanche, L.; Pang, J.; Rode, A.; Soars, M. G.; Unadkat, J. D.; van Waterschoot, R. A.; Yabut, J.; Schinkel, A. H.; Scheer, N. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins Drug Metab. Dispos. 2014, 42 (8) 1301-13 10.1124/dmd.114.057976
34. Ishiguro, N.; Maeda, K.; Kishimoto, W.; Saito, A.; Harada, A.; Ebner, T.; Roth, W.; Igarashi, T.; Sugiyama, Y. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans Drug Metab. Dispos. 2006, 34 (7) 1109-1115 10.1124/dmd.105.009175
35. Ganapathy, V.; Smith, S. B.; Prasad, P. D. SLC19: the folate/thiamine transporter family Pfluegers Arch. 2004, 447 (5) 641-646 10.1007/s00424-003-1068-1
36. Zhao, R.; Diop-Bove, N.; Visentin, M.; Goldman, I. D. Mechanisms of membrane transport of folates into cells and across epithelia Annu. Rev. Nutr. 2011, 31, 177-201 10.1146/annurev-nutr-072610-145133
37. Dervieux, T.; Furst, D.; Lein, D. O.; Capps, R.; Smith, K.; Walsh, M.; Kremer, J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis Arthritis Rheum. 2004, 50 (9) 2766-2774 10.1002/art.20460
38. Laverdiere, C.; Chiasson, S.; Costea, I.; Moghrabi, A.; Krajinovic, M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia Blood 2002, 100 (10) 3832-3834 10.1182/blood.V100.10.3832
39. Konig, J.; Muller, F.; Fromm, M. F. Transporters and drug-drug interactions: important determinants of drug disposition and effects Pharmacol. Rev. 2013, 65 (3) 944-66 10.1124/pr.113.007518
40. Stangier, J.; Su, C. A.; Roth, W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients J. Int. Med. Res. 2000, 28 (4) 149-167 10.1177/147323000002800401
41. Acocella, G. Clinical pharmacokinetics of rifampicin Clin. Pharmacokinet. 1978, 3 (2) 108-127 10.2165/00003088-197803020-00002
42. van Ingen, J.; Aarnoutse, R. E.; Donald, P. R.; Diacon, A. H.; Dawson, R.; Plemper van Balen, G.; Gillespie, S. H.; Boeree, M. J. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin. Infect. Dis. 2011, 52 (9) e194-e199 10.1093/cid/cir184
43. Holmboe, L.; Andersen, A. M.; Morkrid, L.; Slordal, L.; Hall, K. S. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients Br. J. Clin. Pharmacol. 2012, 73 (1) 106-114 10.1111/j.1365-2125.2011.04054.x
44. Nakanishi, T.; Tamai, I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs Drug Metab. Pharmacokinet. 2012, 27 (1) 106-121 10.2133/dmpk.DMPK-11-RV-099